{"schema_version":"secwatch.filing_event.v1","accession":"0001021771-24-000025","form_type":"8-K","ticker":"BRTX","cik":"0001505497","company_name":"BioRestorative Therapies, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.372802+00:00","generated_at":"2026-06-06T10:58:58.041730+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"BioRestorative to present Phase 2 BRTX-100 data at ORS meeting, host webcast Feb 5","bullets":["Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented at ORS 2024 Annual Meeting Feb 2-6 in Long Beach.","Company will host a webcast conference call with slide presentation on Feb 5, 2024 at 8:30 a.m. ET to review the poster.","No specific efficacy or safety results were disclosed in the press release."],"urls":{"canonical":"https://secwatch.observer/filing/0001021771-24-000025","json":"https://secwatch.observer/filing/0001021771-24-000025.json","markdown":"https://secwatch.observer/filing/0001021771-24-000025.md","text":"https://secwatch.observer/filing/0001021771-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000025/0001021771-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1505497/000102177124000025/bio8k2124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:58:58.041730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}